ArticleNutrition & metabolism2026
Mendelian randomization identifies causal effects of phospholipids on portal vein thrombosis risk: FADS1/2-mediated pathways and their potential as diagnostic biomarkers.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEmerging evidence links the plasma lipidome to venous thromboembolism, but its causal relationship with portal vein thrombosis (PVT) remains unexplored. This study aimed to systematically screen for potential causal associations between 179 plasma lipid species and PVT risk, aiming to identify candidate biomarkers and explore underlying biological pathways.
methodsUsing publicly available genome-wide association study (GWAS) data, we performed a two-sample Mendelian randomization (MR) analysis to assess the causal relationships between 179 plasma lipid species and PVT. Inverse-variance weighted (IVW) was the primary method, heterogeneity and pleiotropy were applied to evaluate potential pleiotropy and heterogeneity, and leave-one-out analysis verified result reliability. For lipid species showing nominally significant associations with PVT, lead SNPs were mapped to candidate genes to explore potential biological mechanisms.
resultsIVW analysis identified nominally significant associations (p < 0.05) between 19 lipid species and PVT risk. 11 lipids showed positive associations (OR = 1.517–1.917), predominantly phosphatidylcholine and sterol ester subtypes. Eight lipid species showed inverse associations (OR = 0.479–0.677), predominantly triacylglycerol and phosphatidylinositol subtypes. Sensitivity analyses supported the robustness of these nominal associations, with no evidence of significant heterogeneity or horizontal pleiotropy. Leave-one-out analysis further confirmed the stability of the estimates. However, after multiple testing correction, none of the associations remained statistically significant (all q > 0.05). These nominally associated lipid species were linked through their lead SNPs to key lipid metabolism genes (FADS1, FADS2, APOE, APOA5, LIPC), which have established roles in pathways relevant to thrombosis.
conclusionOur study suggests potential links between specific plasma lipid species and PVT, although these associations did not survive rigorous multiple testing correction. It provides preliminary evidence that certain lipid species, notably phosphatidylcholine and sterol esters, may be implicated in PVT risk. The mapping of these lipids to candidate genes involved in lipid metabolism (FADS1, FADS2, APOE, APOA5, LIPC) offers mechanistic hypotheses for future research. Further studies are required to validate these preliminary associations and assess their translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.